Siemens announces US FDA clearance for its Biograph mMR.
M2 EQUITYBITES-June 13, 2011-Siemens announces US FDA clearance for its Biograph mMR(C)2011 M2 COMMUNICATIONS http://www.m2.com
Supplier of technology to the healthcare industry Siemens Healthcare, a business division of Siemens AG (Frankfurt: SIE) (NYSE:SI), announced on Friday that the US Food and Drug Administration (FDA) has recently granted 510(k) clearance for its Biograph mMR.
The company said that its Biograph mMR is the first system worldwide to enable simultaneous whole-body acquisition of data from magnetic resonance (MR) and positron emission tomography (PET).
The Biograph mMR enables users to generate the location, function and metabolic activity of organs in a single image at the same time. It is designed to provide a more complete diagnostic picture.
Potential clinical applications for molecular MR include the early identification and staging of malignancies, therapy planning and treatment. The Biograph mMR shows the greatest promise in oncologic and neurologic applications where MR and PET have proven their clinical value, Siemens said.
Initial Biograph mMR installations are at the University Hospital in Tuebingen and the University Hospital 'Klinikum rechts der Isar' of the Munich Technical University, both in Germany, and Boston's Massachusetts General Hospital.
((Comments on this story may be sent to firstname.lastname@example.org)).END.PUB430>PDJune 13, 2011>JNM2 EQUITYBITES.PRICEDATENOT APPLICABLE.DAY
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jun 13, 2011|
|Previous Article:||-Medivir not to prolong again takeover offer for Biophausia.|
|Next Article:||Verizona[euro](tm)s request to end printed white paper listing delivery accepted by California PUC.|